Search results
Showing 2656 to 2670 of 8929 results
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Empagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Canagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Dapagliflozin in combination therapy for treating type 2 diabetes: review proposal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 18 March 2026.
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)
Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making
Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making